Facebook tracking pixel
D35.00
ICD-10-CM
Adrenal Nodule

Learn about adrenal nodule diagnosis, including clinical documentation and medical coding for adrenal masses, adrenal tumors, and adrenal lesions. Find information on healthcare best practices for identifying and managing an adrenal mass, adrenal tumor, or adrenal lesion. This resource offers guidance on adrenal nodule diagnosis, supporting accurate medical coding and comprehensive clinical documentation.

Also known as

Adrenal Mass
Adrenal Tumor
Adrenal Lesion

Diagnosis Snapshot

Key Facts
  • Definition : Growth in the adrenal gland, can be benign or cancerous.
  • Clinical Signs : Often asymptomatic. May cause high blood pressure, hormonal imbalances, or abdominal pain.
  • Common Settings : Detected incidentally on imaging (CT, MRI) or during evaluation for hormonal issues.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC D35.00 Coding
E27.1

Hyperplasia of adrenal gland

Overgrowth of adrenal gland tissue, often causing nodules.

D35.0

Benign neoplasm of adrenal gland

Non-cancerous tumors in the adrenal gland.

C74

Malignant neoplasm of adrenal gland

Cancerous tumors of the adrenal gland.

R69.89

Other general symptoms and signs

Can be used for unspecified adrenal abnormalities if others dont fit.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the adrenal nodule functional (hormone-producing)?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Growth in the adrenal gland. Can be benign or cancerous.
Benign adrenal tumor producing excess hormones.
Non-functioning adrenal adenoma. Usually benign and asymptomatic.

Documentation Best Practices

Documentation Checklist
  • Document nodule size, location, and characteristics (e.g., homogenous, heterogeneous).
  • Describe imaging findings: US, CT, or MRI adrenal nodule.
  • Specify if incidental finding or if causing symptoms.
  • Include hormonal evaluation results (if performed).
  • Code using ICD-10 D35.0 Adrenal gland adenoma.

Coding and Audit Risks

Common Risks
  • Laterality Documentation

    Missing documentation specifying right, left, or bilateral adrenal nodule impacts coding accuracy and reimbursement.

  • Benign vs. Malignant

    Incomplete documentation distinguishing benign from malignant adrenal masses affects coding, treatment, and surveillance planning.

  • Incidental vs. Symptomatic

    Lack of clarity on whether the adrenal nodule is incidental or causing symptoms can lead to coding and clinical management discrepancies.

Mitigation Tips

Best Practices
  • Document size, shape, and imaging characteristics for accurate adrenal nodule coding.
  • Use precise adrenal lesion terminology (mass vs. tumor) for compliant clinical documentation.
  • Correlate imaging findings with hormonal evaluation for adrenal mass diagnosis and CDI.
  • For incidentaloma, specify if hormonally active for proper adrenal tumor ICD-10 coding.
  • Regular surveillance imaging crucial for indeterminate adrenal nodules, document follow-up plan.

Clinical Decision Support

Checklist
  • Confirm nodule size and imaging characteristics (ICD-10 E27.8, SNOMED CT 307257003).
  • Assess hormonal function; evaluate for excess cortisol, aldosterone, catecholamines.
  • Review patient history for cancer, hypertension, or other relevant conditions.
  • Consider further imaging (CT, MRI) if indicated for size or characteristics.

Reimbursement and Quality Metrics

Impact Summary
  • Adrenal Nodule (A) reimbursement hinges on accurate coding reflecting size, imaging characteristics, and hormonal function for optimal payment.
  • Coding quality impacts Adrenal Mass/Tumor/Lesion claims. Incorrect laterality or characterization leads to denials, impacting hospital revenue cycle.
  • Adrenal Nodule reporting affects quality metrics tied to incidentaloma management and follow-up imaging compliance, influencing hospital performance scores.
  • Proper documentation of Adrenal Lesion workup (hormonal testing, imaging) supports medical necessity for reimbursement and avoids audits.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: How can I differentiate between benign and malignant adrenal nodules based on imaging characteristics like size, shape, and CT attenuation values?

A: Differentiating benign from malignant adrenal nodules requires a comprehensive evaluation of imaging characteristics. Size is a crucial factor, with nodules larger than 4 cm warranting closer scrutiny for malignancy. Shape and CT attenuation values also provide important clues. Irregular shapes, heterogeneous enhancement, and high attenuation values (especially >10 Hounsfield Units on non-contrast CT) raise suspicion for malignancy. However, these features are not definitive. Washout rate on contrast-enhanced CT can further aid differentiation, with rapid washout suggesting a benign adenoma. Ultimately, a combination of imaging findings, patient risk factors, and hormonal evaluation is often necessary for accurate characterization. Explore how S10.AI can streamline the analysis of adrenal nodule imaging characteristics for improved diagnostic accuracy.

Q: What is the recommended follow-up imaging protocol for incidentally discovered, non-functioning adrenal nodules based on size and risk factors?

A: The recommended follow-up imaging protocol for incidentally discovered, non-functioning adrenal nodules varies based on size and patient-specific risk factors for malignancy. Small, homogenous nodules (<4 cm) with benign imaging characteristics in low-risk patients may not require follow-up imaging. However, nodules between 4-6 cm should typically undergo repeat imaging within 6-12 months. For nodules >6 cm or those with suspicious features, further evaluation with dedicated adrenal protocol CT or MRI is warranted. Patients with a history of malignancy or endocrine disorders require individualized follow-up strategies. Consider implementing S10.AI's decision support tools for personalized adrenal nodule management based on current guidelines.

Quick Tips

Practical Coding Tips
  • Code adrenal nodule specifics
  • Document size, location, features
  • Check laterality ICD-10-CM
  • Rule out malignancy D44.1
  • Review imaging reports carefully

Documentation Templates

Patient presents with concerns regarding a possible adrenal nodule, also referred to as an adrenal mass, adrenal tumor, or adrenal lesion.  Review of systems includes detailed inquiry regarding symptoms such as abdominal pain, flank pain, back pain, unexplained weight changes, changes in blood pressure (including hypertension or hypotension), fatigue, and hormonal imbalances.  Physical examination findings are documented, including palpation of the abdomen and assessment for any signs of Cushing syndrome, Conn syndrome, or pheochromocytoma.  Differential diagnosis includes benign adrenal adenoma, adrenocortical carcinoma, pheochromocytoma, myelolipoma, and metastatic disease.  Diagnostic workup may include abdominal ultrasound, CT scan of the adrenal glands with and without contrast, MRI of the adrenal glands, hormonal blood tests (cortisol, aldosterone, renin, catecholamines), and 24-hour urine collection for metanephrines and catecholamines.  Management plan is based on imaging characteristics, hormonal evaluation, and patient symptoms.  Options include watchful waiting with serial imaging, further biochemical testing, fine-needle aspiration biopsy, or surgical resection (adrenalectomy) for suspicious or symptomatic lesions.  Patient education provided regarding the nature of adrenal nodules, potential complications, and the importance of follow-up care.  ICD-10 codes (e.g., D35.0, D35.1 depending on laterality and specific diagnosis), CPT codes for procedures (e.g., imaging, biopsy, adrenalectomy) will be assigned based on the final diagnosis and treatment plan.  The patient's risk factors, family history, and relevant medical history are documented and considered in the assessment.  Referral to endocrinology or surgical oncology may be warranted depending on the final diagnosis and management plan.